Holen Sie sich die Stockscreener-App
11.47
3.29%
-0.39
Schlusskurs vom Vortag:
$11.86
Offen:
$11.86
24-Stunden-Volumen:
922.20K
Relative Volume:
0.46
Marktkapitalisierung:
$736.65M
Einnahmen:
$161.10M
Nettoeinkommen (Verlust:
$-308.60M
KGV:
-2.4561
EPS:
-4.67
Netto-Cashflow:
$-259.90M
1W Leistung:
-5.67%
1M Leistung:
-1.63%
6M Leistung:
+45.19%
1J Leistung:
-39.28%
1-Tages-Spanne:
$11.37
$11.86
1-Wochen-Bereich:
$11.37
$12.08
52-Wochen-Spanne:
$5.90
$21.00
Arvinas Inc Stock (ARVN) Company Profile
Firmenname
Arvinas Inc
Sektor
Branche
Telefon
203-535-1456
Adresse
395 WINCHESTER AVE, NEW HAVEN, CT
Vergleichen Sie ARVN mit anderen Aktien
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
ARVN
Arvinas Inc
|
11.47 | 761.70M | 161.10M | -308.60M | -259.90M | -4.67 |
|
VRTX
Vertex Pharmaceuticals Inc
|
452.13 | 115.03B | 11.74B | 3.68B | 3.34B | 14.19 |
|
REGN
Regeneron Pharmaceuticals Inc
|
776.31 | 81.12B | 14.25B | 4.58B | 3.88B | 41.77 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
400.17 | 52.54B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
ARGX
Argen X Se Adr
|
839.99 | 51.78B | 3.06B | 1.28B | 447.35M | 19.67 |
|
INSM
Insmed Inc
|
177.12 | 37.12B | 447.02M | -1.18B | -906.14M | -6.1812 |
Arvinas Inc Stock (ARVN) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2025-10-15 | Herabstufung | Goldman | Neutral → Sell |
| 2025-09-24 | Herabstufung | BofA Securities | Buy → Neutral |
| 2025-09-17 | Fortgesetzt | Barclays | Overweight |
| 2025-06-02 | Herabstufung | Leerink Partners | Outperform → Market Perform |
| 2025-05-05 | Herabstufung | Truist | Buy → Hold |
| 2025-05-02 | Herabstufung | Jefferies | Buy → Hold |
| 2025-05-02 | Herabstufung | TD Cowen | Buy → Hold |
| 2025-03-13 | Herabstufung | Goldman | Buy → Neutral |
| 2025-03-12 | Herabstufung | Wedbush | Outperform → Neutral |
| 2025-03-11 | Herabstufung | Oppenheimer | Outperform → Perform |
| 2024-12-10 | Eingeleitet | BTIG Research | Buy |
| 2024-11-18 | Eingeleitet | Stephens | Overweight |
| 2024-02-28 | Bestätigt | Oppenheimer | Outperform |
| 2024-02-14 | Herabstufung | Citigroup | Buy → Neutral |
| 2024-02-01 | Eingeleitet | Goldman | Buy |
| 2023-12-19 | Hochstufung | Wells Fargo | Equal Weight → Overweight |
| 2023-12-06 | Hochstufung | Jefferies | Hold → Buy |
| 2023-11-20 | Hochstufung | Guggenheim | Neutral → Buy |
| 2023-10-23 | Hochstufung | Wedbush | Neutral → Outperform |
| 2023-06-26 | Fortgesetzt | Oppenheimer | Outperform |
| 2023-01-12 | Herabstufung | Guggenheim | Buy → Neutral |
| 2023-01-03 | Herabstufung | Wells Fargo | Overweight → Equal Weight |
| 2022-09-09 | Eingeleitet | Barclays | Overweight |
| 2022-06-21 | Eingeleitet | Jefferies | Hold |
| 2022-05-09 | Herabstufung | Wedbush | Outperform → Neutral |
| 2022-04-28 | Eingeleitet | Credit Suisse | Outperform |
| 2022-04-06 | Eingeleitet | Morgan Stanley | Equal-Weight |
| 2022-02-11 | Fortgesetzt | BMO Capital Markets | Outperform |
| 2022-02-10 | Eingeleitet | Wells Fargo | Overweight |
| 2022-01-19 | Eingeleitet | Goldman | Buy |
| 2021-12-07 | Eingeleitet | Cowen | Outperform |
| 2021-10-14 | Eingeleitet | SVB Leerink | Outperform |
| 2021-09-30 | Eingeleitet | Stifel | Buy |
| 2021-09-09 | Eingeleitet | BofA Securities | Buy |
| 2021-05-21 | Eingeleitet | UBS | Buy |
| 2021-04-21 | Eingeleitet | Truist | Buy |
| 2021-03-31 | Eingeleitet | BMO Capital Markets | Outperform |
| 2020-12-14 | Hochstufung | Oppenheimer | Perform → Outperform |
| 2020-06-01 | Hochstufung | Citigroup | Neutral → Buy |
| 2020-05-12 | Eingeleitet | Oppenheimer | Perform |
| 2019-12-19 | Eingeleitet | H.C. Wainwright | Buy |
| 2019-11-25 | Eingeleitet | Guggenheim | Buy |
| 2019-10-24 | Hochstufung | Goldman | Neutral → Buy |
| 2019-09-25 | Eingeleitet | Wedbush | Outperform |
| 2019-09-12 | Eingeleitet | BMO Capital Markets | Outperform |
| 2019-08-06 | Eingeleitet | Cantor Fitzgerald | Overweight |
| 2019-06-05 | Herabstufung | Citigroup | Buy → Neutral |
| 2019-04-12 | Eingeleitet | Evercore ISI | Outperform |
| 2018-10-22 | Eingeleitet | Citigroup | Buy |
| 2018-10-22 | Eingeleitet | Goldman | Neutral |
| 2018-10-22 | Eingeleitet | Piper Jaffray | Overweight |
Alle ansehen
Arvinas Inc Aktie (ARVN) Neueste Nachrichten
Aug Closing: Is Arvinas Inc stock ready for breakoutEntry Point & Consistent Return Investment Signals - moha.gov.vn
(ARVN) and the Role of Price-Sensitive Allocations - Stock Traders Daily
All You Need to Know About Arvinas (ARVN) Rating Upgrade to Buy - MSN
Arvinas announces preclinical data for ARV-393 - MSN
Can Arvinas Inc. stock sustain institutional interestMarket Movement Recap & Real-Time Chart Pattern Alerts - Улправда
Will Arvinas Inc. stock remain a Wall Street favoriteMarket Movers & Fast Gaining Stock Reports - DonanımHaber
Will Arvinas Inc. stock deliver better than expected guidanceEarnings Recap Report & Reliable Volume Spike Alerts - Улправда
Price Action: Why Arvinas Inc. stock remains on buy listsExit Point & Trade Opportunity Analysis - Улправда
(ARVN) Movement as an Input in Quant Signal Sets - news.stocktradersdaily.com
Possible Bearish Signals With Arvinas Insiders Disposing Stock - simplywall.st
Arvinas Holding Company (ARVN) Receives a Buy from Barclays - The Globe and Mail
Barclays maintains Arvinas (ARVN) overweight recommendation - MSN
Barclays Raises Price Target for Arvinas (ARVN) to $18 | ARVN St - GuruFocus
Caxton Associates LLP Takes $2.19 Million Position in Arvinas, Inc. $ARVN - MarketBeat
Armistice Capital LLC Invests $4.12 Million in Arvinas, Inc. $ARVN - MarketBeat
Arvinas, Inc. (NASDAQ:ARVN) Receives Average Recommendation of "Hold" from Analysts - MarketBeat
Velan Capital Investment Management LP Takes Position in Arvinas, Inc. $ARVN - MarketBeat
Diadema Partners LP Invests $710,000 in Arvinas, Inc. $ARVN - MarketBeat
Arvinas reveals promising preclinical data for ARV-393 - MSN
Arvinas Reveals Promising Preclinical Data for ARV-393 - TipRanks
Arvinas, Inc. Announces Preclinical Data for ARV-393 Combination - TradingView
22NW LP Acquires Shares of 413,533 Arvinas, Inc. $ARVN - MarketBeat
Arvinas (ARVN) Reveals Promising Preclinical Data for Cancer Tre - GuruFocus
Published on: 2025-12-06 23:24:37 - BỘ NỘI VỤ
Arvinas Presents Preclinical Data Supporting Mechanistic Synergies and Enhanced Antitumor Activity with the Combination of ARV-393 and Glofitamab at the 2025 American Society of Hematology Annual Meeting and Exposition - The Manila Times
Arvinas, Inc. Announces Phase 1 Clinical Trial Initiation for ARV-393 Plus Glofitamab in Diffuse Large B-Cell Lymphoma Following Promising Preclinical Data - Quiver Quantitative
Why Arvinas Inc. stock could benefit from AI revolutionProfit Target & AI Forecasted Stock Moves - Newser
Franklin Resources Inc. Grows Stake in Arvinas, Inc. $ARVN - MarketBeat
Why Arvinas Inc. stock is considered a top pickBear Alert & Momentum Based Trading Signals - Newser
ARVN: Robust clinical pipeline advances and strong cash position support growth into 2028 - TradingView
Will Arvinas Inc. stock continue upward momentumIPO Watch & Weekly Watchlist for Hot Stocks - Newser
Arvinas (ARVN) Stock Analysis Report | Ratings, Financials & Performance - Benzinga
How the Narrative Around Arvinas Is Shifting Amid Strategic Moves and Analyst Uncertainty - Yahoo Finance
52,980 Shares in Arvinas, Inc. $ARVN Acquired by SG Americas Securities LLC - MarketBeat
Bronstein, Gewirtz & Grossman, LLC Encourages Arvinas, Inc. (ARVN - The National Law Review
New Highs: Why Arvinas Inc. stock remains on buy listsJuly 2025 Update & Accurate Intraday Trade Tips - moha.gov.vn
Entropy Technologies LP Purchases Shares of 32,491 Arvinas, Inc. $ARVN - MarketBeat
Arvinas Inc Stock Analysis and ForecastLow Beta Stocks & Outstanding Investment Returns - earlytimes.in
Published on: 2025-11-27 09:33:44 - BỘ NỘI VỤ
Arvinas (Nasdaq: ARVN) plans fireside chat at Piper Sandler 37th Healthcare Conference - Stock Titan
Arvinas to Present at Piper Sandler 37th Annual Healthcare Conference - GlobeNewswire
Arvinas to present vepdegestrant breast cancer data at SABCS By Investing.com - Investing.com Nigeria
Arvinas to present vepdegestrant breast cancer data at SABCS - Investing.com
Arvinas, Inc. Announces Multiple Abstract Presentations on Vepdegestrant at San Antonio Breast Cancer Symposium 2025 - Quiver Quantitative
Arvinas Announces Data Presentations from the Vepdegestrant (ARV-471) Clinical Development ... - Enidnews.com
Arvinas Announces Data Presentations from the Vepdegestrant - GlobeNewswire
Arvinas: Approvable, But Asset Looks Mediocre, Initiating With A Hold Rating (NASDAQ:ARVN) - Seeking Alpha
Arvinas (NASDAQ: ARVN) showcases vepdegestrant breast cancer data at 2025 SABCS - Stock Titan
Promising Biotech Stocks To ConsiderNovember 18th - MarketBeat
Can Arvinas Inc. stock beat market expectations this quarterTrend Reversal & Fast Exit/Entry Strategy Plans - newser.com
Arvinas (NASDAQ:ARVN) Stock Price Down 7%Should You Sell? - MarketBeat
Finanzdaten der Arvinas Inc-Aktie (ARVN)
Umsatz
Nettogewinn
Free Cashflow
ENV
Arvinas Inc-Aktie (ARVN) Insiderhandel
| Insiderhandel | Beziehung | Datum | Transaktion | Kosten | #Aktien | Wert ($) | #Aktien Gesamt |
|---|---|---|---|---|---|---|---|
| Morrison Briggs | Director |
Sep 22 '25 |
Buy |
7.57 |
30,000 |
227,010 |
76,021 |
| Saik Andrew | Chief Financial Officer |
Jun 24 '25 |
Sale |
7.61 |
5,700 |
43,377 |
164,401 |
0.57%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):